The World Health Organization (WHO) has recommended GlaxoSmithKline (GSK)’s RTS,S malaria vaccine to be given to children living in sub-Saharan Africa who are at risk of contracting Malaria. RTS,S is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce… Read More
UPM Biomedicals has entered into an agreement with PerkinElmer to act as a distributor of the UPM GrowDex and GrowDase range of products. This new collaboration will offer researchers a complete solution for high throughput screening (HTS) of 3D cell cultures in early drug discovery, combining PerkinElmer’s cell imaging and automation solutions and… Read More
This paid-for advertorial by AB Sciex appeared in DDW Volume 22, Issue 4 – Fall 2021 This high-resolution accurate mass system combines the power of Zeno trap pulsing with EAD fragmentation technology (electron activated dissociation) to uncover structural information, previously inaccessible, and drive the limits of quantification achievable with accurate… Read More
PerkinElmer has launched Signals Image Artist software, an image analysis and management platform for drug discovery research. The new offering is designed to help scientists accurately process and analyse their high-content screening (HCS) and cellular imaging data in a matter of hours, versus days or weeks, so they can make… Read More
Bone Therapeutics and Implant Therapeutics have signed a research evaluation agreement to enable Bone Therapeutics to access, evaluate and materially transfer Implant Therapeutics’ Induced Pluripotent Stem Cell (iPSC) lines, media, differentiation protocols and expertise. Bone Therapeutics has developed a bone marrow-derived off-the-shelf, allogeneic MSC cell therapy platform. Read More
This paid-for advertorial by BMG Labtech appeared in DDW Volume 22, Issue 4 – Fall 2021 The efficacy and safety of drug candidates depends on the affinity to their targets. Since molecular interactions are not static, the affinity of a molecule depends on the speed of binding (association rate) and… Read More
Challenges and Opportunities in Protein Degradation, is free webinar hosted by DDW and supported by Cell Signaling Technology (CST). It took place on 21 October, 2021 and is now available to watch on demand for free here. Dr. Nathanael Gray, Professor of… Read More
A recent sponsored DDW Sitting Down With podcast covered the bamlanivimab story and how this therapeutic went from lab to clinic in eight months during the pandemic. It is available to listen to here. Lu Rahman selects some of the highlights of this chat with Bryan Jones, Senior Research Fellow, BioTechnology Discovery Research, Eli Lilly and Company and Dan Bedinger, Application… Read More
This paid-for advertorial by Twist Biopharma appeared in DDW Volume 22, Issue 4 – Fall 2021 and was written by Melina Mathur, Product Manager for Biopharma at Twist Bioscience. Antibody optimisation is a game of numbers, and the human body is an excellent player. B lymphocytes develop a diverse catalog of antibodies, with… Read More
Given the unexpected couple of years we have had as a result of the Covid-19 pandemic, the drug discovery sector is no doubt looking forward to an in-person event at last. ELRIG UK’s Drug Discovery 2021 will take place at the ACC, Liverpool, UK on 19-20 October. DDW has teamed up with ELRIG UK to produce… Read More
The brain: how much don’t we know? Dr Jim Ross, Chief Technology Officer and Co-founder of Axion BioSystems, asks and discusses the answers to this question. Epilepsy, amyotrophic lateral sclerosis (ALS), Alzheimer’s — we hear these brain disease names all the time, but it feels like we never hear about effective treatments or cures. While medical advances are gradually… Read More
News round-up by DDW’s Megan Thomas for 4-8 October For this week’s drug discovery round up, DDW’s Megan Thomas focuses on stories that provide answers to previously unanswered questions, or news that enables researchers and scientists to find those answers quickly. 1. Novel therapy could… Read More
Dr Michael Fiebig, Chief Scientific Officer, Absolute Antibody offers insight for those starting with a new bispecific antibody project who may feel a little daunted by the wealth of formats out there. Over the past 10-plus years, there has been a dramatic rise in the exploitation of bispecific antibodies with… Read More
The design for two new trials investigating opicapone in the treatment of non-motor symptoms in patients with motor fluctuations in Parkinson’s disease (PD) have been presented at the International Parkinson and Movement Disorder Society’s Virtual Congress (MDS Virtual Congress 2021). Usually associated with motor symptoms, opicapone is a once-daily catechol-O-methyltransferase (COMT) inhibitor, approved in Europe… Read More
Within our drug discovery world, unless we have contact with clinical settings, it is easy to lose sight that our expertise, time, laboratory instruments, software, reagents, tools, workflows and procedures etc. are ultimately designed for the benefit of real-life patients. On 4 November 2021, 9AM PT; 12PM ET; 4PM… Read More
DDW’s Editor Lu Rahman comments and gives perspective on the global drug discovery and development market in the UK. As I’m writing this in the UK, there are reports of gas supply shortages, a lack of CO2 affecting food supply, the price of energy is rising and the cherry on… Read More
